WO2007018318A1 - Procédé pour l'expression génétique propre à un astrocyte cérébelleux et/ou à une cellule à corbeille - Google Patents

Procédé pour l'expression génétique propre à un astrocyte cérébelleux et/ou à une cellule à corbeille Download PDF

Info

Publication number
WO2007018318A1
WO2007018318A1 PCT/JP2006/316127 JP2006316127W WO2007018318A1 WO 2007018318 A1 WO2007018318 A1 WO 2007018318A1 JP 2006316127 W JP2006316127 W JP 2006316127W WO 2007018318 A1 WO2007018318 A1 WO 2007018318A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cerebellar
promoter
synapsin
vector
Prior art date
Application number
PCT/JP2006/316127
Other languages
English (en)
Japanese (ja)
Inventor
Hirokazu Hirai
Takashi Torashima
Original Assignee
National University Corporation Kanazawa University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation Kanazawa University filed Critical National University Corporation Kanazawa University
Publication of WO2007018318A1 publication Critical patent/WO2007018318A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Definitions

  • Cerebellar astrocytes and / X are sputum cell-specific gene expression methods
  • the present invention relates to a cerebellar stellate cell and / or sputum cell-specific gene expression method, a cerebellar function study using the same, and a vector, a transgenic animal, and the like. 'Ming
  • the cerebellum plays an important role in cooperative movements such as walking involving multiple muscles.
  • astrocytes In the cerebellar cortex, there are three types of neurons other than granule cells and Purkinje cells (see Fig. 1). These three types of cells: astrocytes, sputum cells, and Golgi cells are all interneurons, and have the role of regulating signals transmitted to mossy fibers, granule cells, and Purkinje cells.
  • Astrocytes exist in a part of the cerebellar cortex, called a molecular layer, that synapses with the Purkinje cell dendrites and regulates Purkinje cell activity in an inhibitory manner.
  • Vaginal cells are also present in the molecular layer, but unlike astrocytes, they exist near the Purkinje cell layer and form inhibitory synapses with Purkinje cell bodies.
  • cerebellar astrocytes and sputum cells control Purkinje cells in a suppressive manner, but how much these two cells have an effect on Purkinje cells. Contributing to controlled coordination or learning It is completely unknown whether it is.
  • cerebellar stellate cells and sputum cells have been analyzed for their functions by electrically stimulating these cells and recording their potential changes with Purkinje cells or stimulating parallel fibers. Only the method of recording potential changes in cells or sputum cells is known. In addition, since a promoter that specifically functions in cerebellar stellate cells and sputum cells has not been found, transgenic animals with these cell-specific genetic modifications are not known. '
  • Synapsin I is a protein that exists at the end of neurons and plays an important role in the release of synaptic vesicles.
  • synapsin I promoter In Expression analysis using adenoviral vector, synapsin I promoter is reported to function specifically in nerve Rereru (Kugler et al, Molecular and Cellular Neuroscience, 17, p78 -. 96, (2001)) 0 Analyzes using lentiviral vectors have also been remarkably reported that the synapsin I promoter functions in both excitatory and inhibitory neurons in the cerebral cortex (Dittgen et al., PNAS, Vol. 101, No. 52, pl8207-211, (2004)). However, there is no report on how the synapsin I promoter functions in the cerebellum.
  • cerebellum-specific expression vectors are those using adenovirus, adeno-associated virus, or lentivirus, but the promoters used are general CMV promoters, RSV promoters, etc.
  • a cell-specific one there is only a Purkinje cell-specific L7 promoter (Japanese Patent Publication No. 2 0 0 3-5 3 4 7 8 7, Japanese Patent Laid-Open No. 9-2 8 3 7 No. 8 Publication, Special Table 2 0 0 3-5 1 1 0 8 0 Publication).
  • the object of the present invention is to enable gene expression specific to cerebellar astrocytes and / or sputum cells, and to provide a new means for cerebellar function research and gene therapy.
  • synapsin I is a protein that exists at the end of neurons and plays an important role in the release of synaptic vesicles. In general, synapsin I is used as a marker of inspiring presynaptic terminals. Excitatory nerves in the cerebellar cortex are condyles Since it is only granule cells, the inventors considered using the synapsin I promoter as a granule cell-specific expression vector.
  • the synapsin I promoter gene isolated from the rat genome was incorporated into a lentivirus-derived vector, and the GFP gene was ligated downstream of it to infect cells in the cerebellar cortex molecular layer of a living mouse. Localization was observed. Contrary to expectations, no GFP expression was observed in the condylar cells, but instead, selective expression of GFP was confirmed in the astrocytes and sputum cells of the molecular layer.
  • lentiviral vector that expresses GFP under the control of a cell-nonselective CMV promoter or MSCV promoter 3 ⁇ 4 and condylar granule cells do not show GFP expression (the other four types of neurons have GFP Therefore, it was considered that the lentiviral vector does not have the ability to infect granule cells.
  • the present invention has been made based on the above findings, and can function a transgene under the control of the synapsin I promoter. Cerebellar astrocytes of the target animal
  • the present invention relates to a method for specifically expressing the transgene in Z or sputum cells.
  • the transgene is preferably a gene encoding a protein that controls cell survival, a cerebellar development, or a protein that controls physiological functions (for example, a therapeutic protein).
  • a protein that controls cell survival for example, selected from diphtheria toxin, diphtheria toxin receptor, simple herpes-derived thymidine kinase, glutamate receptor, GABA receptor, brain-derived neurotrophic factor, glial cell-derived neurotrophic factor, and variants thereof
  • the gene which codes either can be mentioned.
  • the present invention also includes diphtheria toxin, simple herpes-derived thymidine kinase, glutamate receptor, GABA receptor, brain-derived neurotrophic factor, glial cell-derived neurotrophic factor and variants thereof under the control of synapsin I promoter.
  • Lentivirus-derived vectors that contain a gene that encodes a selected gene or a gene that encodes various therapeutic proteins in a manner that can be linked together, or a transgenic animal into which the vector has been introduced To do.
  • the present invention can also function a transgene under the control of a synapsin I promoter.
  • a lentivirus-derived vector that is ligated and contained in a manner, is inserted into the target animal, and the transgene is specifically expressed in the cerebellar stellate cells and / or sputum cells of the target animal. Also provided are methods for analyzing physiological or pathological functions. .
  • transgenic work products in which a gene encoding one selected from diphtheria toxin, diphtheria toxin receptor, thymidine kinase, Lurcher mutation ⁇ 2 glutamate receptor and its variants is introduced, It is possible to selectively drop cerebellar astrocytes and / or sputum cells, which is useful for elucidating the physiological functions of these two cells and the cerebellum.
  • a lentiviral-derived vector containing a gene encoding a therapeutic protein such as brain-derived neurotrophic factor and glial cell-derived neurotrophic factor under the control of the synapsin I promoter is linked to the cerebellum. It is useful for gene therapy as a therapeutic protein delivery vector to astrocytes and cells or sputum cells.
  • the target animals used in the present invention are non-human mammals, particularly rodents such as mice and rats, in the research field.
  • rodents such as mice and rats
  • gene therapy it is possible to target all mammals including humans.
  • astrocytes and sputum cells can be selectively dropped, and the role of these two types of neurons can be elucidated at the action level such as coordinated movement and motor learning. It becomes.
  • gene expression is limited to astrocytes and Z or sputum cells, and functions of these inhibitory nerves can be regulated, providing a useful means for conducting cerebellar neural circuit research. It will be. Brief Description of Drawings
  • Figure 1 is a schematic diagram of the cerebellar neural circuit. .
  • FIG. 2 is a schematic diagram of pCL20cMS′CV-GFP.
  • FIG. 3A is a schematic diagram of pCL20cSynI, which is an example of the expression vector of the present invention.
  • FIG. 3B is a schematic diagram of pCL20cSynI-GFP, which is an example of the expression vector of the present invention.
  • Figure 3C is a schematic diagram of pCL20cSynI-DTR-HA, which is an example of the expression vector of the present invention. It is. ⁇
  • FIG. 4 is a fluorescence micrograph showing an example of expression of a GFP gene specific to cerebellar astrocytes and sputum cells by pCL20cSynI-GFP.
  • Fig. 5 is a confocal laser micrograph showing an example of expression of GFP gene specific to cerebellar astrocytes and sputum cells by pCL20cSynI-GFP.
  • FIG. 6A is a fluorescence micrograph showing an example of non-selective expression of GFP gene in cerebellar cells by pCL20cMSCV-GFP.
  • FIG. 6B is a confocal laser micrograph showing an example of non-selective expression of GFP gene in cerebellar cells by pCL20cMSCV-GFP.
  • Fig. 7 is a confocal laser micrograph showing an example of expression of GFP gene specific to cerebellar stellate vesicles and sputum cells by pCL20cSynI-DTR-HA.
  • This specification includes the contents described in the specification of Japanese Patent Application No. 2 0 0 5-2 3 1 5 1 4 which is the basis of the priority of the present application.
  • the vector according to the present invention is a lentivirus-derived vector containing a transgene linked in such a manner that it can function under the control of a synapsin I promoter.
  • the vector of the present invention is based on a lentiviral vector derived from human immunodeficiency virus. Unlike adenovirus vectors and herpes virus vectors, lentivirus vectors are advantageous in that they have a very weak immune response in the living body and little cytotoxicity. Examples of the vector derived from the lentivirus include pCL20c (provided by St. Jude Children's Research Hospital), pLenti6 / V5-DEST (manufactured by Invitrogen), and the like.
  • the “basic skeleton” means a structural unit containing factors sufficient to be maintained and replicated in a specific cell. Therefore, in the present invention, A product obtained by removing unnecessary portions from a general-purpose lentivirus-derived vector can also be used. From the viewpoint of improving the titer of the viral vector, for example, in the case of pLenti6 / V5-DEST, which is a lentivirus-derived vector, it is preferable that the portion having the base sequence represented by SEQ ID NO: 7 has been removed.
  • the nucleotide sequence shown in SEQ ID NO: 7 Expression vectors that do not contain are also included in the vector of the present invention.
  • the size of an insert that can be incorporated into a lentiviral vector is generally 8 kb, including plug motors. From the experiments conducted by the inventors so far, it is known that 4 to 5 kb is the limit in the high-titer lentil virus vector from which the portion having the base sequence of SEQ ID NO: 6 is removed. Therefore, in order to express a gene of 3 kb or more, it is necessary to use a neuron-specific promoter that does not exceed 1-2 kb.
  • the vector of the present invention contains a synapsin I promoter as a promoter.
  • the synapsin I promoter sequence is available through public databases such as GenBank.For example, the rat synapsin I promoter sequence is Accession No.
  • the human synapsin I promoter sequence is registered as Accession No. M58321, J05431, M57636.
  • Non-registered synapsin I promoter sequences of other animals can be easily obtained according to a well-known method by homology search based on the above synapsin I promoter sequences.
  • the synapsin I promoter of the present invention includes a modified form thereof (Pariant).
  • the variant may be artificially produced, for example, by a site-directed mutagenesis method according to a conventional method, or may be a naturally occurring variant.
  • SEQ ID NO: 1 shows the rat synapsin I promoter sequence used in the examples of the present efforts (sequence of positions ⁇ 225 to 105 of the rat synapsin I promoter:
  • the present invention is not limited to this sequence.
  • at least one nucleotide residue (preferably one or several) is a different base sequence.
  • it can be expressed specifically in cerebellar stellate cells and / or sputum cells as a synapsin I promoter, it can be expressed in synapsin as well.
  • I promoter It can be used as an I promoter. That is, multiple alignment by the ClustalW method by Higgins et al. (For example, Gappenalty5, Fixed Gap penaltylO, windowssize 5, Floating Gap 10) is aligned to an optimal state, and the calculated sequence identity is at least 80 %, Preferably 85% or more, more preferably 90% or more, and a transgene linked in such a manner that it can function downstream as a synapsin I promoter. Any one having such a base sequence can be used as the synapsin I promoter according to the present invention as long as it can be expressed specifically in cells and cells.
  • a sequence that can hybridize with the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 4 under stringent conditions is also used as a synapsin I promoter, and a transgene linked in a manner that can function downstream thereof is used as a cerebellar star.
  • Dendritic cells and or It can also be used as a synapsin I promoter as long as it can be expressed specifically in sputum cells.
  • the “stringent condition” means 6xSSC (composition of lxSSC: 0.15M NaCl, 0, 015M sodium quenate, ⁇ 7.0), 0.5% SDS, 5 ⁇ Den Hart and 100 / ml denatured fragmented salmon sperm DNA and 50. /.
  • a solution containing formamide together with the nucleic acid consisting of the nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 4, keep it at 55 ° C — low ionic strength, for example, 2xSSC, or more stringent, such as 0.lxSSC Conditions and Z or higher, 37 ° C or higher, stringent 42 ° C or higher, more stringent 50 ° C or higher, even more stringent 60 ° C or higher This can be achieved depending on the conditions under which washing is performed.
  • stringent such as 0.lxSSC Conditions and Z or higher
  • the length of the base sequence of the variant is not particularly limited as long as the desired promoter function is exhibited. However, from the viewpoint of the allowable size of the foreign gene incorporated into the vector, for example, it is 3000 nucleotides or less, preferably 2000 It is desirable that the length be less than or equal to the nucleotide length.
  • the function as a synapsin I promoter can be evaluated, for example, by detecting the presence or absence of binding between the RNA polymerase contained in the cerebellar astrocytes or sputum cells and the nucleic acid to be tested.
  • the presence or absence of binding can be detected by mobility in gel shift assembly, optical sensorgram or mass sensor in surface plasmon analysis, or footprint method.
  • the function of the variant as a promoter is, for example, by linking a reporter gene in a manner that allows it to function downstream of the nucleic acid to be tested, obtaining a construct, and then obtaining the construct from mouse or rat cerebellar glial cells + neurons. It can be assessed by infecting mixed cultures or by administering to the subarachnoid surface of the cerebellum of solid mice.
  • the reporter gene is expressed specifically in cerebellar stellate cells or sputum cells based on the above evaluation, the nucleic acid can be used as a synapsin I promoter suitable for the expression vector of the present invention.
  • synapsin I promoter it is desirable to use a synapsin I promoter sequence of the same species as that of the target animal to be used or a related species.
  • Synapsin I is a protein that exists at the end of neurons and plays an important role in the release of synaptic vesicles. Generally, synapsin I is an excitatory presynaptic Used as a terminal marker. Since the excitatory nerves in the cerebellar cortex are only granule cells, it was considered that the synapsin I promoter could be used as a granule cell-specific expression vector.
  • the inventors incorporated the rat synapsin I promoter gene (SEQ ID NO: 1 and SEQ ID NO: 4) into a vector derived from a lentivirus and ligated the GFP gene downstream thereof, so that the molecular layer of the cerebellar cortex of a living mouse When the cells were infected, no GFP expression was observed in the granule cells. Instead, selective expression of GFP was confirmed in the astrocytes and sputum cells of the molecular layer. That is, it was confirmed that the lentiviral vector using the synapsin I promoter is useful as an expression vector that can specifically function in S-shaped cells and sputum cells.
  • the vector of the present invention comprises a transgene linked in such a manner that it can function under the control of the synapsin I promoter.
  • “connected in a functional manner” means a state in which it is arranged to exert its original function, and is arranged so that the transgene is appropriately expressed under the control of the synapsin I promoter. It means the state that was done.
  • the transgene used in the present invention is not particularly limited.
  • a gene that affects cell survival specifically, a gene encoding a protein that is toxic to the cell
  • the cerebellum Genes encoding proteins that control the development and physiological functions of the genes, specifically genes encoding cerebellar synapse formation and plasticity control molecules, genes that can express proteins and siRNA that can be used for therapeutic purposes, specifically A gene that codes for an enzyme that breaks down or removes aggregates produced in the cell, a gene that encodes a protein that can capture the function of the cell in the cell, and an excessive function in the cell.
  • Genes that can express siRNA that can suppress development other genes that code for proteins related to substance production, and degradation of specific substances
  • Such as genes encoding protein is Chi like.
  • the gene to be introduced includes, for example, a gene encoding diphtheria toxin, a gene encoding diphtheria toxin receptor, and a simple herpes-derived thymidine kinase as a toxic protein.
  • Genes, cerebellum Sina Encodes NMDA glutamate receptor, AMPA glutamate receptor gene, GABA receptor gene, and brain-derived neurotrophic factor or Dariya cell-derived neurotrophic factor for treatment And a gene encoding a dominant negative for functional inhibition, and the like.
  • the expression vector of the present invention only needs to have the structure as described above, and examples thereof include a vector pCL20cSynI (FIG. 3A) having the base sequence shown in SEQ ID NO: 5.
  • the nucleic acid to be introduced can be inserted into the EcoRI and Notl recognition sites in the pCL20cSynI. .
  • the present invention provides a method for introducing a lentivirus-derived vector comprising a transgene linked in a manner capable of functioning under the control of a synapsin I promoter into a target animal, whereby the cerebellar astrocytes and Z or sputum cells of the target animal A method for specifically expressing a transgene is provided. '
  • This method enables the expression and delivery of specific genes specific to cerebellar stellate cells and sputum cells, which was not possible before, researching cerebellar function and treating diseases related to abnormalities of cerebellar stellate cells and sputum cells. And research becomes possible.
  • the vector of the present invention is used to express diphtheria toxin, herpes simplex virus-derived thymidine kinase, Lurcher mutation ⁇ .2 glutamate receptor specifically in cerebellar astrocytes and sputum cells, It is possible to specifically shed these cells: By observing changes due to dropout, it is possible to know the functions of cerebellar astrocytes and sputum cells in the cerebellum. For example, dropping cerebellar stellate cells and sputum cells using this method in young mice leads to the elucidation of the role in cerebellar transduction circuit formation. When used in mature mice, it is clear how these two types of nerves contribute to cerebellar function. In addition, various genes can be specifically expressed in cerebellar stellate cells and sputum cells, and it becomes possible to conduct extensive research on synaptic transmission between cerebellar stellate cells and sputum cells and Purkinje cells.
  • a transgene By injecting the vector of the present invention into the subarachnoid space, a transgene can be expressed specifically in a wide range of cerebellar astrocytes and / or sputum cells of the subject animal.
  • a transgenic animal can be used as, for example, a cerebellar function research model animal or a cerebellar disease model animal.
  • the target of the transgenic animal is not particularly limited, but non-small mammals represented by mice, rats, rabbits, horses, hidges, inu, cats, monkeys, etc. can be used, especially mice. Rodents such as rats are preferred. '3.
  • Lentiviral-derived vectors containing a gene encoding a therapeutic protein linked in a functional manner under the control of the synapsin I promoter are used as gene delivery vectors for cerebellar astrocytes and Z or sputum cells. Useful.
  • the vector of the present invention is dissolved and suspended in a suitable buffer together with a pharmacologically acceptable carrier, injected into the subarachnoid space on the surface of the cerebellum, cerebellar astrocytes and Z or sputum cells. It can be used as a therapeutic agent for diseases caused by disorders in Since the vector of the present invention can efficiently deliver and express a gene encoding a therapeutic protein to cerebellar stellate cells and / or sputum cells, diseases caused by disorders in these cells (as opposed to It is possible to achieve a therapeutic effect with efficiency.
  • Typical examples of secondary astrocyte and sputum cell damage following Purkinje cell degeneration / dropping include spinocerebellar degeneration.
  • Purkinje cell degeneration is prominent in spinocerebellar degeneration type 1, type 2 and type 6. Since astrocytes and sputum cells regulate Purkinje cell activity in a suppressive manner, it may be possible to suppress Purkinje cell degeneration by regulating these cell activities.
  • the pharmacological evaluation of gene therapy varies depending on the type of disease to be treated, but in the case of spinocerebellar degeneration, the vector is administered to the subarachnoid space on the surface of the cerebellum and then cytologically Purkinje cells, stars By preventing degeneration of neurons in the cerebellum, including dendritic cells and sputum cells, clinically (behaviorally in animals) to the extent of improvement in cerebellar ataxia More can be done.
  • the transgene to be incorporated into the vector can be appropriately selected according to the type of disease to be treated.
  • a nucleic acid encoding a brain-derived or glial cell-derived neurotrophic factor can be mentioned.
  • the vector can preferably be administered by injection into the subarachnoid space on the surface of the cerebellum.
  • the injected vector contains a small number of cerebellar astrocytes around the injection site and
  • the active ingredient can be delivered over a wide range with high affinity to cerebellar stellate cells and / or whole sputum cells.
  • injection of the vector of the present invention into the subarachnoid space on the surface of the cerebellum is superior in clinical application because it can suppress damage to the brain parenchyma compared to injection into the lower olive nucleus and the cerebellar nucleus.
  • a means capable of injection at a constant rate for example, a Norton syringe and the like. It is desirable to use a micromanipulator that can be used and a microinjection pump for injection.
  • the injection rate is not particularly limited as long as the brain pressure can be stably maintained, and can be appropriately set according to the age, weight, disease state, etc. of the individual. For example, it is desirable to be lOnl / min to 800 nl / min, preferably 50 nl / min to 400 nl / min, and more preferably lOOnl to 200 nl / min.
  • the dose of the vector of the present invention is not particularly limited as long as it is an amount suitable for exerting a therapeutic effect, and can be appropriately set according to the age, weight, disease state, etc. of the individual.
  • the number of administrations of the therapeutic agent of the present invention is sufficient as long as the therapeutic effect is exhibited.
  • This vector which uses lentivirus as the basic skeleton, can be administered once because the gene is integrated into the chromosome, but in order to increase the copy number of the integrated gene and introduce it into a wider range of cells. In some cases, the surface of the cerebellum may be changed (right, midline, left, etc.) about 3 times.
  • Example 1 Preparation of cerebellar stellate cell and sputum cell-specific expression vector (1) Virus production
  • HEK293T cells in logarithmic growth phase were dispersed in PB $ (—), and then seeded at 5 ⁇ 10 5 cells per l (km dish (manufactured by Falcon)).
  • PB $ (—) the medium in which the cells, 5 vol% C0 2, 37 ° were cultured in C. 24 hours later, the medium in the Deitsushu, new, medium ( was replaced with 10-fold bulk% ⁇ shea fetal serum-containing DMEM) 10 ml. cells then 5 volumes ./. C0 2, 37 ° and 0.5 hours at C.
  • pCL20cSynI-GFP Chil dren's Research Hospital (1 ⁇ g) and pCL20cSynI-GFP (5 g) were each dissolved in 450 to 1 sterile water to obtain a plasmid solution.
  • the pCL20cSynI-GFP is a part of the MSCV promoter of pCL20c MSCV-GFP (St. Jude Children's Research Hospital: SEQ ID NO: 8) shown in FIG. It is replaced with a synapsin I promoter having a base sequence.
  • gag encodes the structural protein of the virus
  • pol codes reverse transcriptase
  • VSVG stands for Vesicular somatitis virus, glycoprotein.
  • the original envelope of lentivirus can only infect CD4 positive cells. By substituting this with a VSV envelope that targets phospholipids, it becomes possible to infect various cells including nerves.
  • pCL20c Lentiviral main vector ", the region between the two LTRs is integrated into the host genome.
  • the medium in the dish was replaced with 10 ml of fresh medium (DMEM containing 10% by weight urchin fetal serum). 'Then cells, 5 volumes. /. They were cultured for 24 hours in C0 2, 37 ° C.
  • the medium was collected from the dish obtained in (1) above, transferred to a 50 ml centrifuge tube, and centrifuged at 1000 rpm (l20 ⁇ g) for 4 minutes to obtain a supernatant.
  • the obtained supernatant was passed through a filter (Millipore, 0.22 / z m diameter).
  • the obtained filtrate was subjected to ultracentrifugation (25,000 rpm, 2 hours, 4 ° C) using Beckman's mouthpiece SW28.1 to precipitate virus particles, and the supernatant was removed.
  • the resulting virus particle precipitate is suspended in phosphate buffered saline (not containing Mg 2+ and Ca 2+ ) [hereinafter PBS (-)] to a final volume of 200 ⁇ 1, for infection.
  • PBS (-) phosphate buffered saline
  • a virus solution was obtained.
  • the virus solution that was not used immediately was dispensed 20 ⁇ l at a time and stored at ⁇ 80 ° C.
  • HeLa cells are cultured in a 10cm dish and infected 24 hours after seeding. Sensation. Three days later, 5.0 ⁇ 10 6 cells were obtained. In parallel, the same number of LAV-8E5 cells (ATCC, Manassas, VA, USA) were obtained. LAV-8E5 cells have one copy of HIV type 1 provirus per cell, and this is the standard. Genomic DNA was extracted from these cells and finally dissolved in 100 1 TE buffer. Of these, 1 and 1 were used to amplify a 290 bp region contained in the HIV provirus RRE (nev responsive element) using the following primers:
  • the copy number of provirus integrated into the genome was determined by serial dilution of genomic DNA. That is, by determining the dilution ratio immediately before the panda disappeared and comparing it with the standard using LAV-8E5 cells, it was determined how many cells per 5.0 X 10 6 HeLa cells. It was calculated whether the provirus was integrated (genome copy number / virus solution lml).
  • the mouse after inoculation with the virus vector is a rack for infected animals equipped with a HEPA filter (trade name: Pioclean Gap Cellulite T- BCC-M4).
  • mice SLC supply, 4-10 weeks old
  • pentobarbital trade name: Nembutal
  • the mouse was fixed using a small animal fixing device [trade name: SG-4, manufactured by Narishige Co., Ltd.].
  • the body temperature of the mouse was maintained at 37 ° C with a body temperature controller [F 'S' T, product name: body temperature control system (for mouse) FST-HPSM].
  • F 'S' T body temperature controller
  • FST-HPSM body temperature control system
  • the skin was incised from the rostral side of several millimeters to just above the cerebellum.
  • a stereomicroscope Nekon Corporation, trade name: 1SMZ645
  • a micro drill Urawa Kogyo, trade name: power controller
  • UC100 + HB1 (drill)] was used to drill holes with an inner diameter of 2 to 3 mm.
  • a hole was made in the dura mater and spider under the bone using an injection needle.
  • the skin of the incised mouse was sutured with an ophthalmic microneedle with a suture thread (trade name. Ophthalmic weak needle C67-0, manufactured by Natsume Seisakusho Co., Ltd.). After that, remove the mouse from the fixing device, and on the heating pad (made by Showa Seiki Kogyo Co., Ltd., trade name: rubber mat heater 1 SG-15) And observed in a cage placed in the safety cabinet. After the mice woke up from anesthesia, the mouse cage was returned to the infected animal rack and maintained for 7-: 14 days.
  • mice were similarly inoculated using a lentiviral vector carrying the MSCV promoter instead of the synapsin I promoter.
  • mice 7 to 14 days after the inoculation the brain was removed after perfusion fixation with 4% formaldehyde-PB. After taking a fluorescent photograph of the whole brain using a fluorescent stereomicroscope, it was treated with 30% sucrose for 24 hours, and then a frozen section was prepared. The prepared brain sections were incubated with the primary antibody (Rat Anti-GFPAb: Nacalai) for 24 hours at room temperature, and then with the secondary antibody (Goat Anti- Rat IgGAb; manufactured by Molecular Probe) for 2 hours. Incubation at room temperature yielded a microscope specimen.
  • the primary antibody Racalai
  • Goat Anti- Rat IgGAb manufactured by Molecular Probe
  • Example 3 Selective elimination of astrocytes and sputum cells by diphtheria toxin GFP of lentiviral vector pCL20cSynI (SEQ ID NO: 5) prepared in Example 1
  • a vector pCL20cSynI-DTR-HA (FIG. 7, SEQ ID NO: 10) was prepared by substituting the cDNA sequence of the diphtheria toxin receptor (DTR) (SEQ ID NO: 9) '.
  • An HA tag sequence for antibody recognition was added to the carboxyl terminus of DTR. According to Example 1, a lentiviral vector for expression of diphtheria toxin receptor was obtained.
  • a lentiviral vector for diphtheria toxin receptor expression was administered into the subarachnoid space of an adult mouse (after 4 weeks of age). 7 days after inoculation 20 (day 9 am and 8 pm) Diphtheria toxin dissolved in PBS at a concentration of 1 ⁇ g / ml (manufactured by Rubiochem) 150 / zl (diphtheria toxin 150 ng) Inoculated intraperitoneally for a total of 7 days. Thereafter, perfusion fixation was performed with 4% formaldehyde-PB, and the brain was removed.
  • the diphtheria toxin receptor is selectively expressed in astrocytes and sputum cells, and this can be achieved by continuous administration of diphtheria toxin. It was thought that two types of cells had dropped out.
  • gene expression limited to astrocytes and sputum cells can be studied, and a useful means for studying the function of the cerebellum will be provided.
  • astrocytes and sputum cells by selectively dropping out astrocytes and sputum cells, it is possible to elucidate the role of these two types of neurons at the behavioral level such as coordinated movement and motor learning.
  • the present invention can be used for gene therapy targeting astrocytes and sputum cells.
  • SEQ ID NO: 1 rat synapsin I promoter (Synlp) _ 2 25 ⁇ : part of L05 position
  • SEQ ID NO: 2 rat of rat synapsin I promoter (Synlp) 2 2 5 to position 105 to 105 part, '
  • SEQ ID NO: 4 rat synapsin I promoter (Synlp)-941-105 position
  • SEQ ID NO: 5 artificial sequence description: pCL20cSynI (Synlp is rat 1046 bp)
  • SEQ ID NO: 6 artificial sequence description: pCL20cSynI-GFP (Synlp is 1046bp of rat)
  • SEQ ID NO: 7 Description of artificial sequence: Sequence containing SV40 promoter and Blasticidine resistance gene
  • SEQ ID NO: 8 Description of artificial sequence: pCL20cMSCV-GFP
  • SEQ ID NO: 9 Description of one artificial sequence: diphtheria toxin receptor (DTR) cDNA sequence
  • SEQ ID NO: 10 Description of one artificial sequence: diphtheria toxin receptor (DTR) cDNA sequence
  • DTR diphtheria toxin receptor
  • SEQ ID NO: 10 Description of one artificial sequence: pCL20cSynI DTR-HA (Synlp is rat 1046 bp)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé pour l'expression génétique propre à un astrocyte cérébelleux et/ou à une cellule à corbeille. Ce procédé permet d'exprimer un gène propre à un astrocyte cérébelleux et/ou à une cellule à corbeille d'un animal cible, recouvrant l'étape de l'introduction d'un vecteur dérivé d'un lentivirus transférant le gène dans l'animal cible, où le gène est rattaché au vecteur de telle sorte que le gène peut fonctionner sous le contrôle du promoteur de synapsin I ; il comporte également une étude de la fonction du cervelet et propose un vecteur, un animal transgénique ou similaire pour les besoins du procédé ou de l'étude..
PCT/JP2006/316127 2005-08-10 2006-08-10 Procédé pour l'expression génétique propre à un astrocyte cérébelleux et/ou à une cellule à corbeille WO2007018318A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005231514 2005-08-10
JP2005-231514 2005-08-10

Publications (1)

Publication Number Publication Date
WO2007018318A1 true WO2007018318A1 (fr) 2007-02-15

Family

ID=37727483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/316127 WO2007018318A1 (fr) 2005-08-10 2006-08-10 Procédé pour l'expression génétique propre à un astrocyte cérébelleux et/ou à une cellule à corbeille

Country Status (1)

Country Link
WO (1) WO2007018318A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2318537A1 (fr) * 2008-08-07 2011-05-11 Her Majesty The Queen In Right of Canada as represented by The Minister of Health Séquence promoteur optimisée
WO2015164739A1 (fr) * 2014-04-25 2015-10-29 Bluebird Bio, Inc. Récepteurs d'antigènes chimères kappa/lambda
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US10479975B2 (en) 2014-06-06 2019-11-19 Bluebird Bio, Inc. Methods of making T cell compositions
US10774343B2 (en) 2014-04-25 2020-09-15 Bluebird Bio, Inc. MND promoter chimeric antigen receptors
US11299752B2 (en) 2015-05-13 2022-04-12 Csl Behring Gene Therapy, Inc. Bio-production of lentiviral vectors
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
US12006369B2 (en) 2014-07-24 2024-06-11 2Seventy Bio, Inc. BCMA chimeric antigen receptors
US12109234B2 (en) 2016-11-04 2024-10-08 2Seventy Bio, Inc. Anti-BCMA CAR T cell compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000051A1 (fr) * 1991-06-28 1993-01-07 The Regents Of The University Of Michigan Traitement de pathologies par instillation sitospecifique de cellules ou par transformation sitospecifique de cellules et trousses prevues a cet effet
JP2006050956A (ja) * 2004-08-11 2006-02-23 Japan Science & Technology Agency プルキンエ細胞における遺伝子の発現のための発現ベクター

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000051A1 (fr) * 1991-06-28 1993-01-07 The Regents Of The University Of Michigan Traitement de pathologies par instillation sitospecifique de cellules ou par transformation sitospecifique de cellules et trousses prevues a cet effet
JP2006050956A (ja) * 2004-08-11 2006-02-23 Japan Science & Technology Agency プルキンエ細胞における遺伝子の発現のための発現ベクター

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOULOS S. ET AL.: "Assessment of CMV, RSV and SYN1 promoters and the woodchuck post-transcriptional regulatory element in adenovirus vectors for transgene expression in cortical neuronal cultures", BRAIN RESEARCH, vol. 1102, June 2006 (2006-06-01), pages 27 - 38, XP005573371 *
DITTGEN T. ET AL.: "Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo", PROC. NATL. ACAD. SCI. U.S.A., vol. 101, 2004, pages 18206 - 18211, XP003003909 *
KOGLER S. ET AL.: "Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units", VIROLOGY, vol. 311, 2003, pages 89 - 95, XP004432847 *
KOGLER S. ET AL.: "Neuron-specific expression of therapeutic proteins: Evaluation of different cellular promoters in recombinant adenoviral vectors", MOLECULAR AND CELLULAR NEUROSCIENCE, vol. 17, 2001, pages 78 - 96, XP003003910 *
MORIMOTO S. ET AL.: "Glia- and neuron-specific expression of the rennin-angiotensin system in brain alters blood pressure, water intake, and salt preference", J. BIOL. CHEM., vol. 277, no. 36, 2002, pages 33235 - 33241, XP003003911 *
SCOTT B.B. AND LOIS C.: "Generation of tissue-specific transgenic birds with lentiviral vectors", PROC. NATL. ACAD. SCI. U.S.A., vol. 102, November 2005 (2005-11-01), pages 16443 - 16447, XP003003912 *
TORASHIMA T. ET AL.: "In vivo transduction of murine cerebellar Purkinje cells by HIV-derived lentiviral vectors", BRAIN RESEARCH, vol. 1082, March 2006 (2006-03-01), pages 11 - 22, XP005364137 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2318537A4 (fr) * 2008-08-07 2012-01-18 Ca Minister Health & Welfare Séquence promoteur optimisée
EP2318537A1 (fr) * 2008-08-07 2011-05-11 Her Majesty The Queen In Right of Canada as represented by The Minister of Health Séquence promoteur optimisée
US10774343B2 (en) 2014-04-25 2020-09-15 Bluebird Bio, Inc. MND promoter chimeric antigen receptors
WO2015164739A1 (fr) * 2014-04-25 2015-10-29 Bluebird Bio, Inc. Récepteurs d'antigènes chimères kappa/lambda
US10479975B2 (en) 2014-06-06 2019-11-19 Bluebird Bio, Inc. Methods of making T cell compositions
US11560547B2 (en) 2014-06-06 2023-01-24 2Seventy Bio, Inc. Methods of making T cell compositions
US12006369B2 (en) 2014-07-24 2024-06-11 2Seventy Bio, Inc. BCMA chimeric antigen receptors
US11020466B2 (en) 2014-12-12 2021-06-01 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US11633463B2 (en) 2014-12-12 2023-04-25 2Seventy Bio, Inc. BCMA chimeric antigen receptors
US10639358B2 (en) 2014-12-12 2020-05-05 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US10639359B2 (en) 2014-12-12 2020-05-05 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US12029784B2 (en) 2014-12-12 2024-07-09 2Seventy Bio, Inc. BCMA chimeric antigen receptors
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US11351236B2 (en) 2014-12-12 2022-06-07 2Seventy Bio, Inc. BCMA chimeric antigen receptors
US11382965B2 (en) 2014-12-12 2022-07-12 2Seventy Bio, Inc. BCMA chimeric antigen receptors
US10646558B2 (en) 2014-12-12 2020-05-12 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US10624960B2 (en) 2014-12-12 2020-04-21 Bluebird Bio, Inc. BCMA chimeric antigen receptors
AU2016261864B2 (en) * 2015-05-13 2022-05-26 Csl Behring Gene Therapy, Inc. Bio-production of lentiviral vectors
US11299752B2 (en) 2015-05-13 2022-04-12 Csl Behring Gene Therapy, Inc. Bio-production of lentiviral vectors
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
US12109234B2 (en) 2016-11-04 2024-10-08 2Seventy Bio, Inc. Anti-BCMA CAR T cell compositions

Similar Documents

Publication Publication Date Title
WO2007018318A1 (fr) Procédé pour l'expression génétique propre à un astrocyte cérébelleux et/ou à une cellule à corbeille
US12097268B2 (en) Modulation of neural pathways
RU2737049C2 (ru) Лечение пигментного ретинита
JP2021097675A (ja) 中枢神経系を標的化したａａｖベクター
Blacklaws Small ruminant lentiviruses: Immunopathogenesis of visna-maedi and caprine arthritis and encephalitis virus
JP2024023294A (ja) 遺伝子編集のためのｃｐｆ１関連方法及び組成物
JP7430652B2 (ja) 蝸牛および前庭細胞に核酸を送達するための組成物および方法
US9579362B2 (en) Splice variants of GDNF and uses thereof
US9434781B2 (en) Method for augmenting vision in persons suffering from photoreceptor cell degeneration
CA3128525A1 (fr) Agents therapeutiques interneurones specifiques permettant de normaliser l'excitabilite des cellules neuronales et de traiter le syndrome de dravet
US8278284B2 (en) Therapeutic agents for diseases associated with apoptotic degeneration in ocular tissue cells that use SIV-PEDF vectors
KR20210132109A (ko) Dna-결합 도메인 전사활성화제 및 이의 용도
Sugano et al. Establishment of effective methods for transducing genes into iris pigment epithelial cells by using adeno-associated virus type 2
US20230181767A1 (en) Compositions and methods for promoting hair cell regeneration
KR20230041965A (ko) Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법
CN114555100A (zh) 用于治疗阿尔兹海默症的组合物和方法
JP2013034401A (ja) アストロサイトで遺伝子を発現させるためのベクター
JP2006050956A (ja) プルキンエ細胞における遺伝子の発現のための発現ベクター
CN111093716A (zh) 用于治疗神经性疼痛的方法和组合物
US20230241166A1 (en) Ultra-sensitive step-function opsin for minimally invasive optogenetic stimulation
US20240158810A1 (en) Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
CN117642187A (zh) 用于治疗听力损失的基因疗法构建体和方法
CN116710566A (zh) Neurod1载体
CN116782921A (zh) Neurod1组合载体
JP2006223162A (ja) 腎マクラデンサ細胞の単離・識別方法、不死化腎マクラデンサ細胞の樹立方法及びその細胞株並びに形質転換動物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06796484

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP